Cerevel Therapeutics Holdings, Inc. (CERE)
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Cerevel Therapeutics Holdings, Inc. (“Cerevel” or “the Company”) (NASDAQ: CERE). Investors who purchased Cerevel securities prior to October 11, 2023, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation.
Cerevel Investigation Details
The investigation concerns whether Cerevel and certain of its officers and/or directors have engaged in corporate wrongdoing.
What’s Next for Cerevel Investors?
If you are aware of any facts relating to this investigation or purchased Cerevel securities, you can assist this investigation. You can also contact Peretz Bronstein or his client relations manager, Nathan Miller, of Bronstein, Gewirtz & Grossman, LLC: 917-590-0911.
No Cost to Cerevel Investors
We, Bronstein, Gewirtz & Grossman, LLC, represent investors in class actions on a contingency fee basis. That means we will ask the court to reimburse us for out-of-pocket expenses and attorneys’ fees, usually a percentage of the total recovery, only if we are successful.
Why Bronstein, Gewirtz & Grossman, LLC For Cerevel Securities Investigation?
Bronstein, Gewirtz & Grossman, LLC is a nationally recognized firm that represents investors in securities fraud class actions and shareholder derivative suits. Our firm has recovered hundreds of millions of dollars for investors nationwide.
“Our practice centers on restoring investor capital and ensuring corporate accountability, which serves to uphold the essential integrity of the marketplace,” said Peretz Bronstein, Founding Partner of Bronstein, Gewirtz & Grossman, LLC.
Follow us for updates on LinkedIn, X, Facebook, or Instagram.
Contact Info
Peretz Bronstein, Esq. or Nathan Miller
Bronstein, Gewirtz & Grossman, LLC
917-590-0911 | [email protected]
Attorney advertising.
Prior results do not guarantee similar outcomes.